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Corticosteroids like dexamethasone (DEX) are well-established treatments for the glomerular disease that sustain renal function,
at least in part, by protecting podocytes from apoptotic death. In this study, we found that PAN causes abnormal expression of the
PI3K-bindingproteinCD2AP,reducingPI3K/Aktsignalingandpromotingpodocyteapoptosis.Incontrast,DEXrestoresCD2AP-
PI3K-Akt-GSK3𝗽signaling,whichpromotestheactivityofantiapoptoticproteinsandinhibitstheactivityofproapoptoticproteins.
In addition, we also found that CD2AP was aberrantly colocalized with p85. Normal CD2AP mRNA expression and subcellular
protein distribution were maintained in the PAN+DEX group, and DEX coapplication also reduced CD2AP-p85 colocalization.
PAN evoked a concentration-dependent decrease in p-Akt and p-GSK3𝗽 expressions, with p-Akt expression reaching a nadir
at 15min and p-GSK3𝗽 expression at 30min. DEX treatment induced a concentration-dependent reversal of PAN-induced p-
Akt and p-GSK3𝗽 downregulation. The PI3K inhibitor LY294002 blocked p-Akt and p-GSK3𝗽 expressions in podocytes. Cells
treated with PAN exhibited a significantly higher apoptosis rate than untreated or vehicle-treated cells. Furthermore, LY294002
exacerbated PAN-induced apoptosis. DEX cotreatment caused a significant concentration-dependent decrease in PAN-induced
apoptosis. These results strongly suggest that DEX protects podocytes by stabilizing the expression and subcellular distribution of
CD2AP and by maintaining the expression of phosphor-activated Akt and GSK3𝗽.
1. Introduction
Corticosteroids are widely used to treat glomerular dis-
ease. Recent studies demonstrated functional receptors for
corticosteroids on glomerular podocytes [1], suggesting
that clinical effects may be mediated by the rescue of
podocyte function. Corticosteroids like DEX increase the
stability of the cytoskeletal protein F-actin in podocytes and
inhibit PAN-induced podocyte apoptosis. The cytoskeletal-
associated protein CD2AP regulates cytoskeletal structure
andcellmorphologybydirectlybindingtoactinandavariety
of membrane anchoring proteins. DEX improves podocyte
survival by upregulating the expressions 𝗼-tubulin, CD2AP,
and the transmembrane slit diaphragm protein nephrin.
In addition, DEX downregulates the expression of vascular
endothelial growth factor (VEGF) [2]. Wada et al. [3]f o u n d
that DEX inhibited PAN-induced podocyte apoptosis by
downregulating the expression of p53, upregulating Bcl-xL,
and delaying the translocation of apoptosis-inducing factor
(AIF) from cytoplasm to nucleus. Wada et al. [4]a l s of o u n d
that PAN decreased the phosphorylation of extracellular
signal-regulated kinase (ERK) and that DEX reversed this
effect.
However,therehavebeennoreportsexaminingthedirect
effects of DEX on intracellular signaling pathways that may
contribute to this antiapoptotic effect in podocytes. The
PI3K/Akt signal pathway is widely distributed in eukaryotes
and plays essential roles in growth, differentiation, prolif-
eration, and survival. It is possible that DEX and other
corticosteroids protect podocytes and improve proteinuria
by activating the PI3K/Akt signaling pathway, but this has
yet to be demonstrated. The purpose of this study was
to determine if phosphoactivation of PI3K/Akt and the
downstream target GSK3𝗽 is necessary for the anti-apoptotic
effects of DEX against PAN-induced apoptosis in cultured
mouse podocytes.2 BioMed Research International
2. Materials and Methods
2.1. Cell Culture. Conditionally immortalized mouse podo-
cyte clone (a kind gift from Professor Peter Mundel, USA)
was cultured at 33
∘C in RPMI-1640 containing 10% fetal
bovine serum (Gibco, Gaithersburg, MD, USA), 100U/mL
penicillin/streptomycin, and 10U/mL of mouse recombinant
r-interferon (PEPRO Tech, London, UK) and then shifted to
37
∘C for differentiation by removal of r-interferon which had
typical character of mature podocyte after two weeks, In the
studies described below, all experiments were performed in
growth-restricted podocytes and repeated three times.
2.2. RT-PCR Analysis. Total RNA was extracted from podo-
cyte using TRIzol Reagent according to the manufacturer’s
instruction,andtheRNAconcentrationwasdeterminedafter
t h es a m p l ew a sd i s s o l v e di nd i e t h y l p y r o c a r b o n a t e - t r e a t e d
water. Isolated RNA (1𝜇g) of each sample was subjected
to reverse transcription by using Rever Tra Ace (TOYOBO
Co., Japan) according to the manufacture’s protocol. The
resulting cDNA (3𝜇L) was used for PCR amplification. The
sequence-specific primers were designed and synthesized by
Shanghai Invitrogen Biotechnology Co, Ltd. Primers used
were as follows: CD2AP upstream and downstream primers,
respectively,were,Forward:5-GCTCCTTCCTGACCCACT-
3.Reverse:5-TAAAAATACCCACCGCCA-3,productlength
being 238bp; GAPDH upstream and downstream primers
were, Forward: 5-GGTGAAGGTCGGTGTGAACGGAT-3,
Reverse: 5-CCACTTTGCCACTGCAAATGGCAG-3 prod-
uct length being 118bp. The PCR amplification was started
with 2min of denaturation at 95
∘C, which was followed by
34 cycles (for GAPDH, 30 cycles) of denaturation at 95
∘C
for 30s, annealing at 58
∘Cf o r3 0s( G A P D H ,5 5
∘Cf o r3 0s ) ,
and polymerization at 72
∘Cf o r4 5s( G A P D H ,30s ) .Th efi n a l
extension lasted 7min at 72
∘C and then ended at 4
∘C. PCR
products (5𝜇L) were separated on 1% ethidium bromide-
stained agarose gels and later scanned with gel imaging
system (Bio Rad Company A). Independent experiment was
repeated 3 times.
2.3.WesternBlotAnalysis. Podocyteswerelyzedinthebuffer
containing 1% Tritonx-100, 150mM NaCl, 1mM EDTA,
50mM Tris-HCl (pH 7.7), 1mM NaF, 1mM NaVO3, and a
protease inhibitor cocktail (Sigma Chemical Co.). Seventy-
five micrograms of total protein was loaded to run 8%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
( S D S - P A G E ) ,a n dt h eg e lw a ss e tu pf o rt r a n s f e rp r o t e i n
to nitrocellulose membranes (Sigma Chemical Co.). Then,
the membranes were rinsed in a Tris-buffered saline with
0.02% Tween 20 (TTBS) and followed by immersing in 5%
low-fat milk. Subsequently, the membranes were incubated
with rabbit anti-first antibody (Sigma Chemical Co.), mouse
anti-GAPDH antibody (Sigma Chemical Co.). After rinsing
three times with TTBS, the membranes were incubated
with HRP-conjugated goat anti-rabbit or mouse IgG (Sigma
Chemical Co.) for 45min at room temperature and then
developed using ECL chemiluminescence reagent (Sigma
Chemical Co.). The specific protein bands were scanned and
quantitated using densitometry in relation to the GAPDH,
western blotting detection system (GE Healthcare, Chalfont
S t .G i l e s ,U K ) .W er e p e a t e de a c hw e s t e r nb l o ta n a l y s i su s i n g
protein from three different and separate experiments.
2.4. Immunofluorescence. First, antibody was fixed with 4%
paraformaldehydethenpermeabilizedandblockedwith0.3%
TritonX-100 and 5% bovine serum albumin. The primary
antibody, rabbit anti-first antibody (Sigma Chemical Co.),
was applied for overnight at 4
∘C. FITC-conjugated goat anti-
rabbitormouseIgG(SigmaChemicalCo.)andthenucleidye
Hoechst was used for 45min at room temperature. Finally,
the coverslips were mounted and images were taken by using
an immunofluorescence microscope (Zeiss, Germany). we
counted at least 200 nuclei in triplicate in each experiment.
2.5. Confocal Fluorescence Microscopy. Podocytes were cul-
turedonglassslidesandexposedtoexperimentalconditions.
Cells were fixed with 4% paraformaldehyde and perme-
abilized with 0.1% Triton-X for 5 minutes. Blocking was
p e r f o r m e dw i t h1 0 %f e t a lb o v i n es e r u m .P r i m a r ya n t i b o d y
was incubated at 4
∘C for 12 hours. Secondary antibody
was incubated for 1 hours at room temperature. Cells were
visualizedbyconfocalmicroscopy.Blu-raywasdetectedwith
Zeiss LMS-inverted confocal microscope equipped with a
488nm laser and with a 543nm laser for green, using a Zeiss
×40 objective. Laser power and photomultiplier setting were
kept identical for all samples to make the results comparable.
Images were recorded and analyzed with the Zeiss LMS510
software (EMBL, Germany).
2.6. Statistical Analysis. Data were reported as mean ±
SD with 𝑛 equal to the number of experiments. Statistical
evaluation was performed using a one-way ANOVA (two-
sided test) followed by LSD (equal variances assumed) or
Dunnett’s T3 (equal variances not assumed) for post hoc test
b e t w e e nt w og r o u p sa n da l s ou s i n gt h en o n p a r a m e t r i ct e s t s
(Mann-Whitney𝑈-test)asaposttest.Valuesof𝑃 < 0.05were
considered as a statistical significance.
3. Results
3.1. Changes in the Expression and Distribution of CD2AP
mRNA. The expression of CD2AP mRNA in podocytes
was significantly decreased 8h after the application of PAN
compared to expression of the internal reference GAPDH,
and this downregulation was maintained for up to 48h
in PAN. Downregulation of CD2AP was reversed by DEX
coapplication.ExpressionofCD2APmRNAwassignificantly
higher in cultures treated with PAN + DEX compared to
c u l t u r e st r e a t e dw i t hP A Na l o n ea t2 4ha n d4 8h( 𝑃 < 0.05);
indeed, CD2AP mRNA expression in PAN + DEX cultures
was not significantly lower than in vehicle-treated control
cells (Figure 1).
3.2. Changes in Colocalization of CD2AP and p85. In con-
trol, immunofluorescence examination revealed that CD2AP
was evenly distributed in the nuclear envelope, cytoplasm,BioMed Research International 3
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Figure1:ChangesinrelativeexpressionofCD2APmRNA(CD2AP
/GAPDH) for the control group, PAN-treated group, and PAN +
DEX group at different time points. Note: By single factor analysis
of variance, PAN-triggered group versus control group,
∗𝑃 < 0.05;
DEX-treated group versus PAN group,
#𝑃 < 0.05.
and plasmamembrane. Following PAN treatment, however,
CD2AP was distributed in granules within the cytoplasm,
perinuclear region, and nucleus, but was largely absent from
the plasma membrane and most regions of the cytoplasm.
DEX cotreatment reversed these changes in CD2AP dis-
tribution over time. In PAN + DEX cultures, CD2AP was
distributed over a larger area of cytoplasm and plasma
membrane, although granules were still observed in the
c y t o p l a s m4 8 ha ft e rP A N+D E Xt r e a t m e n t .I nc o n t r o l
cultures, overlap between CD2AP and the PI3K subunit
p85 was observed in the nuclear envelope, cytoplasm, and
plasma membrane. PAN-treated cultures exhibited signifi-
cantly greater fluorescence overlap in the nucleus, and this
change in subcellular distribution was reversed by DEX
cotreatment; DEX treatment significantly enhanced fluores-
cence overlap in the perinuclear region and reduced overlap
in the nucleus (Figure 2).
3.3. Decreasing Akt and GSK3𝗽 Phosphorylation by PAN
and Reversal by DEX. PAN induced both concentration-
and time-dependent changes in the expression of p-Akt as
revealed by Western blotting (Figure 3) .I nt h ep r e s e n c eo f
PAN (50g/mL), podocyte p-Akt reached a nadir at 15min.
As little as 12.5g/mL caused a significant decreased in p-Akt
expression and expression decreased progressively as PAN
concentrations increased from 12.5 to 50, 70, and 100𝜇g/mL.
Similar to the effect on CD2AP expression and subcellular
distribution, the effect of PAN on Akt phosphorylation was
reversed by DEX cotreatment and the reversal was DEX
concentration dependent. The phosphorylation of Akt in
PAN + DEX group podocytes approached that of control
cultures. Pretreatment with LY294002 (25M) for 1h almost
completely blocked Akt phosphorylation (Figure 3).
3.4. PAN-Induced Suppression of p-GSK3𝗽. PAN treatment
also exerted concentration- and time-dependent changes in
the expression of p-GSK3𝗽,w i t ht h el a r g e s td e c r e a s ei n
p-GSK3𝗽 expression observed at 30min after PAN appli-
cation. PAN decreases podocyte p-GSK3𝗽 at 12.5𝜇g/mL,
and expression progressively decreased as PAN concentra-
tions increased (50, 70, and 100𝜇g/mL). The effect of PAN
was reversed by DEX (10𝜇mol/L) co-treatment. Expression
of p-GSK3𝗽 was almost completely blocked by LY294002
(25mmol/L) for 1h (Figure 4).
3.5. PAN-Induced Apoptosis and Rescue by DEX Cotreatment.
PAN-treated podocytes showed greatly enhanced apoptosis
after 24h treatment compared to control and vehicle-treated
(0.02% DMSO) cultures. Apoptosis was even higher after
48h of PAN treatment and most podocytes were apoptotic
by 72h. The PAN + DEX group showed significantly lower
apoptosis rates than the PAN-treated group at all time
points.PretreatmentwithLY294002exacerbatedapoptosisat
(Figure 5).
4. Discussion
Podocytes are highly differentiated, morphologically com-
plex epithelial cells consisting of the cell body, primary pro-
cess,andalargesecondaryprocessorfootprocess.Podocytes
are an important structural and functional component of
the glomerular filtration membrane and the last protective
barrier against protein leakage. Podocyte impairment is a
k e yp a t h o g e n i ce v e ni nt h ei n i t i a t i o na n dd e v e l o p m e n to f
glomerular diseases associated with proteinuria. In the early
stages of glomerular disease, there are significant changes in
anatomic relationship between adjacent podocyte foot pro-
cesses and between foot processes and the basement mem-
brane, resulting in enhanced protein permeability resulting
in proteinuria.
Podocyte apoptosis can be induced by PAN, angiotensin-
II (Ang II), cyclosporine A, and by stretching. It is generally
believed that podocytes are terminally differentiated nonre-
generativecellswithlimitedhealingcapacity.Thus,apoptosis
l e a d st oa ni r r e v e r s i b l ed e c r e a s ei nt h en u m b e ro fp o d o c y t e s .
The filtration barrier becomes incomplete, allowing blood
proteins to penetrate this filtration membrane. The recent
discovery of podocyte slit diaphragm-associated molecules
l i k en e p h r i nh a sl e dt oag r e a t e re m p h a s i so nt h em o l e c u l a r
mechanisms and signal pathways that regulate glomeru-
lar permeability. Recent studies on monogenetic inherited
nephrotic syndrome (NS) and primary NS have revealed
many protein molecules specifically expressed in podocytes,
such as nephrin, CD2AP, podocin, and TRPC [5–7]. These
podocyte-associated proteins are regulated by and activate
signal pathways that maintain the normal structure and
function of podocytes and the slit diaphragm.
The phosphoinositide-3-kinases (PI3Ks) specifically cat-
alyze the phosphorylation of the hydroxyl group on the 3
position of phosphatidylinositol (PI). Normally, PI3Ks cat-
alyze formation of the lipid products 3,4-diphosphate phos-
phatidylinositol (PI(3,4)P2) and 3,4,5-triphosphate phos-
phatidylinositol (PI(3,4,5)P3), both of which act as second
messengers to activate the downstream signaling molecules4 BioMed Research International
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Figure 2: Changes in the co-localization of CD2AP and p85 in control cultures, PAN-treated cultures and PAN + DEX co-treated cultures
as revealed by immunocytochemistry under confocal laser scanning microscopy (600x). In control cultures, significant overlap between the
green fluorescent staining of CD2AP and the red fluorescent staining of p85 was observed in the cytoplasm, plasmamembrane, and nucleus.
PAN-treatedculturesshoweddecreasedoverlapinthecytoplasmat24and48h,butenhancedco-stainingofthenuclearenvelopeandnucleus.
Reduced nuclear fluorescence overlap at 24h and 48h in PAN + DEX co-treated cells.
protein kinase B (PKB/Akt) and glycogen synthesis kinase-
3𝗽(GSK-3𝗽).Manydownstreamtargetproteinsarethenacti-
v a t e dt h r o u g hA k t -a n dG S K - 3 𝗽-mediated phosphorylation.
These signaling cascades ultimately regulate such diverse
cellular processes as proliferation, differentiation, survival,
and translocation. The serine/threonine kinase Akt is central
to PI3K-initiated cell signaling and is essential in such phys-
iological and pathological processes such as angiogenesis,
telomerase activation, and cell invasion, as well as in the
modulation of cell cycle regulation and cell apoptosis.
The PI3K-Akt-GSK3𝗽1 pathway is involved in the initia-
tionanddevelopmentofhumanrenaldiseases.Transforming
growth factor 𝗽1( T G F 𝗽1) acts on renal tubular epithelial
cells to increase the phosphorylation of Akt, which results
in reduced GSK3𝗽 kinase activity, promoting the transcrip-
tion of proteins associated with the epithelial-mesenchymal
transitional (EMT) [8]. The CD2AP protein contains one
binding site for actin, one sequence abundant in proline, and
threecontinuousSH3(Srchomology3)domains.Interaction
between the C terminal of CD2AP and the intracellular C
terminalofnephrinstabilizestheslitdiaphragm.Inaddition,
the interaction of CD2AP with the cytoskeleton is regulated
b yr e c e p t o r so nt h es u r f a c eo fp o d o c y t e s[ 9]. Decreased
expression of CD2AP was observed in a PAN-induced ratBioMed Research International 5
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Figure 3: Changes in p-Akt/Akt induced by PAN, PAN + DEX, and LY294002 in podocytes. (a) p-Akt/Akt after 0, 15, 30, 45, 60, and 120min
of PAN (50𝜇g/mL).(b)Concentration-dependenceofPAN-induced changes inp-Akt/Akt asmeasuredat15minaftertreatmentwith0,12.5,
2 5 ,5 0 ,7 0 ,o r1 0 0𝜇g/mL PAN. (c) Reversal of the PAN response by DEX co-treatment and effect of LY294002 at 30min. Lane 1: Control
group, Lane 2: DMSO (0.02%), Lane 3: PAN (50𝜇g/mL), Lanes 4–6: PAN (50𝜇g/mL) + DEX (0.1, 1, or 10𝜇mol/L), Lane 7: Pretreatment with
LY294002 for 1 hour + PAN (50𝜇g/mL) + DEX (10𝜇mol/L) for 30min. Lysates from podocyte treatment groups were collected for Western
blot examination to detect the expression of p-Akt and total Akt.
∗𝑃 < 0.05 and
∗∗𝑃 < 0.01 compared to the control group;
#𝑃 < 0.05
compared to PAN-treated group; in comparison with DEX-treated group
∗,
#𝑃 < 0.01.
model of nephropathy [10, 11], while increased expression of
CD2AP was observed in an adriamycin-induced nephrotic
(ADN) rat model [12]. Despite reciprocal changes in expres-
sion,abnormalsubcellularCD2APdistributionwasobserved
in both models, suggesting that changes in the molecular
interactions of CD2AP with other proteins rather than
expression levels per se mediate kidney injury in response to
PAN and adriamycin.
Huber et al. [13] foundthatp85 immunoprecipitatedwith
both CD2AP and nephrin in transfected HEK293T cells,
indicating the presence of a nephrin-CD2AP-p85 complex.
A k t ,t h ed o w n s t r e a mt a r g e tm o l e c u l eo fP I 3 K ,i sa c t i v a t e di n
HEK293T cells overexpressing nephrin and CD2AP. When
transfected with nephrin cDNA, conditionally immortalized
podocytes showed increased Akt activity. Wortmannin, a
specific inhibitor of PI3K, can completely block the activity
of Akt. Therefore, it is possible that the interaction between
CD2AP, nephrin, and p85 promotes the translocation of
PI3K to the plasmalemma, activating the PI3K/Akt signaling
pathway. Fan et al. [14] found that gene knockdown of
CD2AP, nephrin, or podocin led to abnormal expressions
of PI3K and Akt. Huber et al. [15]a l s of o u n dt h a tp o d o c i n
overexpression in HEK293 cells promoted nephrin phospho-
rylation,activationofp38MAPK,andincreasedtranscription6 BioMed Research International
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Figure 4: Suppression of GSK3𝗽 phosphorylation by PAN and reversal by DEX. (a) p-GSK3𝗽/GSK3𝗽 at 0, 15, 30, 45, 60, and 120min in
PAN (50 𝜇g/mL) as revealed by Western blotting. (b) Concentration dependence of the PAN effect as indicated by Western blots after 30min
treatmentwith0,12.5,25,50,70,and100𝜇g/mL PAN. (c) Reversal by DEX co-treatment and effect of LY294002. Lane 1: Control group, Lane
2: DMSO (0.02%), Lane 3: PAN (50𝜇g/mL), Lanes 4–6: PAN (50𝜇g / m L )+D E X( 0 . 1 ,1 ,a n d1 0𝜇mol/L), Lane 7: One hour pretreatment with
LY294002 before PAN (50 𝜇g/mL) + DEX (10𝜇mol/L) for 30min.
∗𝑃 < 0.05,
∗∗𝑃 < 0.01 compare to control group;
#𝑃 < 0.05 compared to
the PAN-treated group;
#𝑃 < 0.01 compared to the DEX-treated group.
factor AP-1 activity. Woroniecki et al. [16]f o u n dt h a tT G F - 𝗽
expression was increased by 1.5-fold in CD2AP−/− animals.
When stimulated by TGF-𝗽, PI3K and ERK1/2 were rapidly
phosphorylated to an early peak in wild-type cells, while
CD2AP−/− podocytes showed delayed peak PI3K/ERK1/2
phosphorylation in response to TGF-𝗽.Th u s ,i ti ss u g g e s t e d
t h a tC D 2 A Pi si n v o l v e di nt h eT G F - 𝗽-induced activation
of PI3K and ERK1/2. Tossidou et al. [17]a c t i v a t e dg r o w t h
factor receptor tyrosine kinases (RTKs) in podocytes and
observed disordered PI3K/Akt and ERK signaling responses.
Xavier et al. [18] found that CD2AP can directly interact
with the TGF-𝗽 receptor subunit TbetaRI at the cytoplasmic
tail and mediate the interaction between Tbeta RI and the
PI3K regulatory subunit p85, activating the PI3K/Akt signal
pa th waytoinhibitTbeta-inducedpodocytea poptosis.Zh uet
al. [19] transfected podocytes with rat nephrin and podocin
genes and observed the phosphorylation of the PI3K/Akt
pa th wa yaswellasincr easedactivi tyo fRac1.H uberetal.[20]
demonstrated that lipid raft complex of podocin can recruit
t h ei o nc h a n n e lp r o t e i nT R P C 6t ot h eS Da n dr e g u l a t ei t s
functions. Zhang et al. [21] suggested that Ang II-induced
podocyte apoptosis might be related to TRPC6 upregulation,BioMed Research International 7
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PAN + 10 𝜇mol/L DEX.
ERK activation, and NF-𝜅B translocation. Wada et al. [4]
suggested that DEX exerts antiapoptotic effects by stabilizing
ERK pathway.
Podocyte damage is also related to podocyte apoptosis
caused by the inhibition of the Akt pathway [22]. Xiao et al.
[23] observed significant podocyte apoptosis, a decreased p-
Akt/Akt ratio, and increased activity of the TGF pathway
in the PAN nephropathy rat model, suggesting that PAN
inducespodocyteapoptosisbyactivatingTGF-𝗽/Smadwhile
b l o c k i n gt h eP I 3 K / A k tp a t h w a y .Th es t u d yb yW a d ae ta l .[ 3]
showed that apoptosis of cultured podocytes in vitro was
significantly increased by PAN treatment (30g/mL) for 48h
and that apoptosis was significantly decreased by DEX.
They further found that PAN induces podocyte apoptosis
by upregulating p53 and Bax proteins and downregulating
antiapoptotic Bcl-2. In contrast, DEX inhibits PAN-induced
damage by downregulating p53 and Bax expression while
upregulatingantiapoptoticBcl-2expression.Themostrecent
study by Wada et al. [4] demonstrated that PAN also
decreased phosphorylation of ERK in podocytes and that8 BioMed Research International
reduced p-ERK was inhibited by DEX, suggesting that DEX
exerts antiapoptotic effects on podocytes by stabilizing the
phosphorylation of ERK.
In this study, we observed a significant decrease in
CD2AP mRNA expression over 48 hours of PAN treatment.
In 24 hours, the subcellular distribution of CD2AP was
significantly altered in the plasma membrane and cytoplasm.
By 48 hours, we observed CD2AP translocation into the
nucleus. Colocalization of CD2AP with p85 was also altered
by PAN, with decreased fluorescence overlap and accumu-
lation in nuclei. Thus, we suggest that PAN inhibits the
transcription of CD2AP mRNA and decreases the synthesis
of CD2AP protein, which leads to inadequate CD2AP in
the slit diagram, impairing diaphragm integrity and normal
binding between CD2AP and p85. To test whether abnormal
binding between CD2AP and p85 interferes with the activa-
t i o no ft h ed o w n s t r e a mm o l e c u l eA k t ,w et r e a t e dp o d o c y t e s
with PAN (50g/mL) and measured the expression of p-Akt
p r o t e i na t0 ,1 5 ,3 0 ,4 5 ,6 0 ,a n d1 2 0m i na n df o u n dt h a tt h e
expression of p-Akt decreased significantly compared to the
control group at 15min. We also treated podocytes with 6
PAN concentrations (0, 12.5, 25, 50, 75, and 100g/mL) and
measured the expression of p-Akt at 15min, finding that
PAN evoked a concentration-dependent decrease in p-Akt
that was statistically significant for high PAN concentration
(75 and 100g/mL). Furthermore, these high PAN concentra-
tions also induced apoptotic cell death in most podocytes,
strongly suggesting that p-Akt mediates apoptotic resistance
in podocytes. We also observed a similar trend in p-GSK3𝗽,
findingdecreasedp-GSK3𝗽at15,30,and45min(withanadir
at 30min) and a similar concentration-dependent decrease
in p-GSK3𝗽 expression, which was statistically significant at
higher PAN concentrations (75 and 100g/mL).
The bcl-2-associated death promoter Bad can form het-
erologous dimers with Bax or Bak, replacing the Bax in
heterologous dimers such as Bcl-2/Bax and Bcl-xl/Bax in a
concentration-dependent manner. We speculate that PAN
decreases the transcription of CD2AP, leading to lowered
expression and abnormal subcellular distribution, which
interferes with the interaction between CD2AP and p85,
therebyreducingPI3K/Aktsignalactivationanddownstream
activation of antiapoptotic factors. DEX can increase the
transcription of CD2AP and the expression of proteins and
promote localization to the slit diaphragm, thus maintaining
the integrity of the SD. DEX also facilitates the normal
bindingbetweenCD2APandp85,whichactivatesPI3K,Akt,
and GSK3𝗽 and exerts antiapoptotic effects on podocytes.
DEX also demonstrated a concentration-dependent inhibi-
t i o no fP A N - i n d u c e dp o d o c y t ea p o p t o s i sa n dr e v e r s e dP A N -
induced downregulation of p-Akt and p-GSK3𝗽. Indeed,
the expression of p-Akt and p-GSK3𝗽 was near that of
untreated control cultures when 10g/mL DEX was added to
50g/mL PAN. When pretreated with LY294002 for 1h, the
phosphorylation of Akt and GSK3𝗽 in podocytes was almost
completely blocked. Moreover, DEX cotreatment reduced
BadexpressioncomparedtoP ANalone.W esuggestthatDEX
stabilizes the transcription and normalizes the subcellular
distribution of CD2AP. The binding of CD2AP to p85
activates the PI3K/Akt signal pathway, which then phospho-
activates and phospho-inhibits various downstream target
proteins. When phosphorylated, Bad affinity to various Bcl-
2 protein family members is altered. Bad phosphorylation
facilitates that activity of anti-apoptotic proteins, thereby
promotingthesurvivalandapoptoticresistanceofpodocytes.
In summary, PAN causes abnormal expression of the
PI3K-binding protein CD2AP, reducing PI3K/Akt signaling
and promoting podocyte apoptosis. In contrast, corticos-
teroidslikeDEXrestoreCD2AP-PI3K-Akt-GSK3𝗽signaling,
which promotes the activity of anti-apoptotic proteins and
inhibits the activity of proapoptotic proteins. Further studies
are required to unravel the additional molecular details of
this cytoprotective pathway for the treatment of glomerular
diseases.
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